LIXTE Amends S-1 for Public Offering, Updates Executive Info
Ticker: LIXT · Form: S-1/A · Filed: Jun 24, 2025 · CIK: 1335105
| Field | Detail |
|---|---|
| Company | Lixte Biotechnology Holdings, INC. (LIXT) |
| Form Type | S-1/A |
| Filed Date | Jun 24, 2025 |
| Risk Level | high |
| Sentiment | neutral |
Sentiment: neutral
Topics: Biotechnology, S-1/A Filing, Public Offering, SEC Filing, Smaller Reporting Company, Pharmaceuticals, Capital Raise
Related Tickers: LIXT
TL;DR
**LIXTE's S-1/A is a procedural step towards a capital raise, but the lack of financial specifics makes it a 'wait and see' for traders.**
AI Summary
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) filed an S-1/A on June 24, 2025, as an amendment to its initial S-1 registration statement, indicating a proposed public sale of securities. The company, classified under Pharmaceutical Preparations (SIC 2834), is a non-accelerated filer and a smaller reporting company, suggesting a smaller market capitalization and fewer public reporting requirements. The filing lists Geordan Pursglove as the Chief Executive Officer and agent for service, with principal executive offices now located in Pasadena, CA, a change from its previous East Setauket, NY address. While specific revenue and net income figures are not detailed in this amendment, the S-1/A primarily updates administrative and legal information related to the offering. Key risks for LIXT, typical for a biotechnology firm, include the inherent uncertainties of drug development, clinical trial outcomes, and regulatory approvals, which are critical for its strategic outlook. The strategic outlook centers on advancing its pharmaceutical pipeline, contingent on successful capital raises from this offering.
Why It Matters
This S-1/A filing signals LIXTE's continued efforts to raise capital through a public offering, which is crucial for funding its drug development pipeline. For investors, it means a potential opportunity to invest in a smaller reporting biotechnology company, albeit with higher inherent risks due to its early stage. Employees and customers will be impacted by the company's ability to secure funding, which directly affects its operational stability and product development timelines. In the competitive biotech landscape, successful capital raises are vital for LIXTE to compete with larger pharmaceutical companies and advance its drug candidates.
Risk Assessment
Risk Level: high — LIXTE is classified as a 'smaller reporting company' and a 'non-accelerated filer,' indicating a smaller market capitalization and potentially less mature operations compared to larger, more established companies. As a biotechnology firm (SIC 2834), it faces inherent high risks associated with drug development, clinical trial failures, and regulatory hurdles, which are not mitigated by this administrative S-1/A filing.
Analyst Insight
Investors should approach LIXTE with caution, recognizing the high-risk profile of a smaller reporting biotechnology company. Await the full S-1 filing for detailed financial statements, pipeline specifics, and a comprehensive risk factors section before making any investment decisions.
Executive Compensation
| Name | Title | Total Compensation |
|---|---|---|
| Geordan Pursglove | Chief Executive Officer |
Key Numbers
- 2025-06-24 — Filing Date (Date S-1/A was filed with the SEC)
- 333-288120 — Registration Number (Unique identifier for the S-1/A registration statement)
- 2834 — SIC Code (Primary standard industrial classification for Pharmaceutical Preparations)
- 1231 — Fiscal Year End (LIXTE's fiscal year ends on December 31st)
- 631-830-7092 — Business Phone (Registrant's principal executive offices phone number)
Key Players & Entities
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. (company) — Registrant in S-1/A filing
- Geordan Pursglove (person) — Chief Executive Officer and agent for service
- David L. Ficksman, Esq. (person) — Counsel from TroyGould PC
- TroyGould PC (company) — Legal counsel for the registrant
- Anthony W. Basch, Esq. (person) — Counsel from Kaufman & Canoles
- Kaufman & Canoles (company) — Legal counsel for the registrant
- SEC (regulator) — Securities and Exchange Commission
- 0001641172-25-016163 (regulator) — Accession Number for the S-1/A filing
- 333-288120 (regulator) — Registration No. for the S-1/A filing
- 2834 (regulator) — Standard Industrial Classification (SIC) code for Pharmaceutical Preparations
FAQ
What is the purpose of LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s S-1/A filing?
The S-1/A filing by LIXTE BIOTECHNOLOGY HOLDINGS, INC. on June 24, 2025, is an amendment to its initial S-1 registration statement, primarily to update administrative and legal information in preparation for a proposed public sale of securities.
Who is the Chief Executive Officer of LIXTE BIOTECHNOLOGY HOLDINGS, INC.?
Geordan Pursglove is listed as the Chief Executive Officer of LIXTE BIOTECHNOLOGY HOLDINGS, INC. and also serves as the agent for service for the company.
Where are LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s principal executive offices located?
LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s principal executive offices are located at 680 East Colorado Boulevard, Suite 180, Pasadena, CA 91101, with a business phone number of (631) 830-7092.
What is LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s SIC code?
LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Is LIXTE BIOTECHNOLOGY HOLDINGS, INC. considered a smaller reporting company?
Yes, LIXTE BIOTECHNOLOGY HOLDINGS, INC. has indicated by check mark that it is a 'smaller reporting company' in its S-1/A filing, which affects its reporting requirements.
What is the fiscal year end for LIXTE BIOTECHNOLOGY HOLDINGS, INC.?
LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s fiscal year ends on December 31st, as indicated by the '1231' value in the filing data.
What are the potential risks for investors in LIXTE BIOTECHNOLOGY HOLDINGS, INC.?
Investors in LIXTE BIOTECHNOLOGY HOLDINGS, INC. face high risks typical of a biotechnology company, including uncertainties in drug development, clinical trial outcomes, and regulatory approvals, compounded by its status as a smaller reporting company.
Which law firms are providing counsel for LIXTE BIOTECHNOLOGY HOLDINGS, INC. in this filing?
TroyGould PC, represented by David L. Ficksman, Esq., and Kaufman & Canoles, represented by Anthony W. Basch, Esq., are providing legal counsel for LIXTE BIOTECHNOLOGY HOLDINGS, INC. in connection with this S-1/A filing.
When was the S-1/A filed by LIXTE BIOTECHNOLOGY HOLDINGS, INC.?
The S-1/A was filed by LIXTE BIOTECHNOLOGY HOLDINGS, INC. on June 24, 2025, with the SEC, as indicated by the 'FILED AS OF DATE: 20250624' in the header.
Has LIXTE BIOTECHNOLOGY HOLDINGS, INC. changed its name recently?
Yes, LIXTE BIOTECHNOLOGY HOLDINGS, INC. was formerly known as SRKP 7 INC, with the name change occurring on August 3, 2005.
Risk Factors
- Drug Development and Approval Uncertainty [high — regulatory]: The company's success is heavily dependent on the successful development and regulatory approval of its pharmaceutical products. This process is inherently lengthy, expensive, and uncertain, with no guarantee of success. Clinical trial failures or delays can significantly impact the company's ability to generate revenue.
- Need for Future Capital [high — financial]: As a biotechnology company, LIXTE requires substantial capital for research, development, clinical trials, and commercialization. This S-1/A filing indicates a proposed public sale of securities, highlighting the ongoing need for funding. Failure to secure adequate financing could impede its strategic objectives.
- Competition in the Pharmaceutical Sector [medium — market]: The pharmaceutical industry is highly competitive, with numerous established companies and emerging biotechs vying for market share. LIXTE faces competition from companies with greater financial resources, established market presence, and advanced research capabilities.
- Reliance on Key Personnel [medium — operational]: The company's ability to advance its pipeline and achieve its strategic goals relies on the expertise of its management team and scientific staff. The loss of key personnel could disrupt operations and negatively impact development progress.
Industry Context
LIXTE BIOTECHNOLOGY HOLDINGS, INC. operates in the Pharmaceutical Preparations industry (SIC 2834). This sector is characterized by high R&D investment, lengthy product development cycles, and stringent regulatory oversight from bodies like the FDA. The competitive landscape includes large, established pharmaceutical giants and numerous smaller biotech firms, all vying for breakthroughs in drug discovery and market approval.
Regulatory Implications
As a pharmaceutical company, LIXTE is subject to extensive regulatory scrutiny. The success of its drug candidates hinges on navigating complex clinical trial phases and obtaining approvals from regulatory agencies. Any missteps in compliance or failure to meet rigorous standards can lead to significant delays, increased costs, or outright rejection of products.
What Investors Should Do
- Review the full S-1/A filing for detailed risk factors and use of proceeds.
- Assess the company's cash burn rate and future financing needs.
- Monitor clinical trial progress and regulatory milestones.
Key Dates
- 2025-06-24: Filing of S-1/A Amendment — Indicates the company is actively pursuing a public offering of securities to raise capital, signaling a key step in its strategic growth plan.
- 2025-06-23: Filing as of Date — Represents the most recent date for which information in the filing is considered current, important for assessing the company's immediate status.
- 2005-08-03: Date of Name Change from SRKP 7 INC — Marks a historical corporate identity change, potentially reflecting a strategic shift or rebranding effort in the company's past.
Glossary
- S-1/A
- An amendment to a registration statement filed with the U.S. Securities and Exchange Commission (SEC) on Form S-1. It is used to update or correct information in the original S-1 filing before it becomes effective. (This filing indicates LIXTE is in the process of registering securities for a public offering, which is a critical step for raising capital.)
- SIC Code 2834
- Standard Industrial Classification code for Pharmaceutical Preparations. This industry includes companies that manufacture medicinal and botanical drugs and herbs. (Classifies LIXTE within the pharmaceutical sector, highlighting its core business and the industry-specific risks and opportunities it faces.)
- Non-accelerated filer
- A category of filer with the SEC that does not meet the thresholds for accelerated filer status. They have fewer ongoing reporting requirements. (Indicates LIXTE is likely a smaller company with less stringent reporting obligations, which can affect the depth of publicly available financial information.)
- Smaller reporting company
- A classification by the SEC for companies with a public float below a certain threshold. These companies have reduced disclosure requirements. (Further reinforces that LIXTE is likely a smaller entity, impacting the scope and detail of financial data typically provided in filings.)
- Rule 415
- SEC rule that permits securities to be registered for the 'shelf' and offered on a delayed or continuous basis. This is often used for ongoing capital-raising activities. (The absence of a checkmark for Rule 415 suggests this specific offering is not intended for continuous or delayed sale under this rule, implying a more discrete offering.)
Year-Over-Year Comparison
This S-1/A filing is an amendment to a previous registration statement, not a comparison to a prior year's financial report. As such, direct year-over-year comparisons of financial metrics like revenue growth or margin changes are not applicable. The primary focus of this amendment is to update administrative and legal information related to the proposed public offering of securities, rather than to present updated financial performance data.
Filing Details
This Form S-1/A (Form S-1/A) was filed with the SEC on June 24, 2025 by Geordan Pursglove regarding LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT).